It sounds like more research and clinical testing is needed for glutamate-targeted therapeutics like sarcosine, with a focus on early treatment.
CONCLUSIONS:
Problems to overcome for successfully leveraging glutamatergic agents for schizophrenia are patient selection, focus on positive symptoms and late disease stages, and dose-response relationships.
Because glutamate guides processes of brain development and maturation, clinical research should focus on the at-risk mental state or first-episode psychosis, address cognition and negative symptoms and use monotherapy designs in parallel to augmentation strategies.